News items ScreenPoint Medical raises 28 million for further development

2 August 2021

ScreenPoint Medical has raised $28 million in a Series C financing. New York-based Insight Partners led the round, with support from existing investors, including ScreenPoint Medical's founders Siemens Healthineers and Oost NL, and participation from the U.S. University Radiology Group (URG). ScreenPoint Medical is a spin-off of the Radboudumc.

Early detection

ScreenPoint Medical is an AI technology company developing advanced image recognition and machine learning software to improve early detection of breast cancer. The new funding will be used by the company to accelerate the commercial growth of the company's Transpara AI software and improve the early diagnosis of breast cancer. One in eight women will develop breast cancer in their lifetime and early detection is the best way to increase survival rates. The investment will enable further research & development, as well as an expansion of the product portfolio.

Expansion in the US

"We are excited about this funding and the opportunity to work with the Insight Partners team to further scale the company," said Nico Karssemeijer, CEO of ScreenPoint Medical. "We are also pleased with URG's participation in this round, which shows confidence in the technology we are bringing to market. The practice of breast imaging is different in the US than in the EU. Collaboration with URG provides clinical expertise that is extremely valuable for further expansion in the US. This round puts ScreenPoint Medical in an excellent position to become the leading provider of AI-driven breast imaging solutions."

Source: ScreenPoint Medical

More information


Pieter Lomans

persvoorlichter

send an email

Related news items


Aiosyn and Radboudumc are the first in the Netherlands to implement AI in the clinical pathology workflow Digital pathology slides will be screened with a quality control algorithm

4 April 2022 Aiosyn, a company that develops AI-powered computational pathology analysis for clinical diagnostics, and the department of pathology of Radboudumc, will collaborate to implement an algorithm for quality control of digitized histopathology tissue slides. read more

Tailored drug dosage for pregnant women

14 March 2022 Three quarters of women in the Netherlands use some form of medication during pregnancy, but little is known about the appropriate dosages. Research by the Radboudumc, MUMC+ and Lareb Mothers of Tomorrow should change this. read more

LUMO Labs and Oost NL invest in Aiosyn Investment accelerates development of artificial intelligence platform to improve diagnostics

7 February 2022 Aiosyn, a spin-off from Radboudumc, has received an investment from LUMO Labs. Oost NL is a co-investor. read more

Epigenetics: Immunization is passed on to offspring Mice transmit adaptations to infections to next generations

19 October 2021 Does an infection affect the immunization of subsequent generations? It does, according to research now published in Nature Immunology. read more

New start-up Patholyt will bring AI research into pathology diagnostics

21 September 2021 Patholyt is on a mission to accelerate the adoption of artificial intelligence in pathology diagnostics and improve the chances of cancer patients worldwide. Patholyt is a spin-off from Radboudumc, a frontrunner in computational pathology research. read more

Human microbiome could shed light on higher morbidity rate in minoritized populations The link between environmental inequities and disease may lie in the gut

15 June 2021 A study published in PNAS is the first to explicitly address the gut microbiome as a pathway to understanding how environmental inequities could lead to health disparities. read more